Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives $20.75 Consensus PT from Analysts

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has earned an average recommendation of “Buy” from the seven brokerages that are presently covering the company, Marketbeat.com reports. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $21.00.

Several brokerages have commented on ZVRA. William Blair upgraded shares of Zevra Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. HC Wainwright increased their target price on Zevra Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Friday, September 20th. JMP Securities began coverage on Zevra Therapeutics in a research report on Tuesday. They set an “outperform” rating and a $17.00 target price for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zevra Therapeutics in a research note on Wednesday, August 14th. Finally, Roth Mkm lifted their price objective on shares of Zevra Therapeutics from $19.00 to $21.00 and gave the stock a “buy” rating in a research note on Tuesday.

Zevra Therapeutics Price Performance

Shares of ZVRA stock opened at $8.27 on Wednesday. The firm has a market cap of $346.12 million, a price-to-earnings ratio of -6.13 and a beta of 1.94. Zevra Therapeutics has a 12 month low of $3.89 and a 12 month high of $8.95. The company has a quick ratio of 2.00, a current ratio of 2.00 and a debt-to-equity ratio of 1.80. The stock has a 50-day moving average price of $7.10 and a 200 day moving average price of $5.73.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.01). Zevra Therapeutics had a negative return on equity of 124.85% and a negative net margin of 274.10%. The business had revenue of $4.45 million for the quarter, compared to analyst estimates of $4.08 million. During the same quarter in the prior year, the firm earned ($0.15) EPS. Research analysts expect that Zevra Therapeutics will post -1.58 EPS for the current year.

Insider Activity

In other Zevra Therapeutics news, Director Thomas Anderson bought 10,000 shares of the stock in a transaction that occurred on Tuesday, July 16th. The stock was acquired at an average cost of $6.81 per share, with a total value of $68,100.00. Following the purchase, the director now owns 20,000 shares in the company, valued at $136,200. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders have acquired 22,000 shares of company stock worth $140,340 in the last 90 days. Corporate insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On Zevra Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ZVRA. Price T Rowe Associates Inc. MD acquired a new stake in shares of Zevra Therapeutics in the 1st quarter valued at about $64,000. The Manufacturers Life Insurance Company grew its holdings in shares of Zevra Therapeutics by 15.2% during the second quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock worth $91,000 after buying an additional 2,452 shares in the last quarter. IFG Advisors LLC raised its position in Zevra Therapeutics by 45.0% in the 1st quarter. IFG Advisors LLC now owns 18,700 shares of the company’s stock valued at $108,000 after buying an additional 5,800 shares during the last quarter. Focus Financial Network Inc. ADV bought a new stake in Zevra Therapeutics in the 4th quarter valued at approximately $141,000. Finally, Virtu Financial LLC acquired a new position in Zevra Therapeutics during the 4th quarter worth approximately $177,000. 35.03% of the stock is owned by institutional investors and hedge funds.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.